CoChat

A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1

Open access
Gallage, Suchira, Ali, Adnan, Barragan Avila, Jose Efren, Seymen, Nogayhan, Ramadori, Pierluigi, Joerke, Vera, Zizmare, Laimdota, Aicher, David, Gopalsamy, Indresh K., Fong, Winnie, Kosla, Jan, Focaccia, Enrico, Li, Xin, Yousuf, Suhail, Sijmonsma, Tjeerd, Rahbari, Mohammad, Kommoss, Katharina S., Billeter, Adrian, Prokosch, Sandra, Rothermel, Ulrike, Mueller, Florian, Hetzer, Jenny, Heide, Danijela, Schinkel, Benjamin, Machauer, Tim, Pichler, Bernd, Malek, Nisar P., Longerich, Thomas, Roth, Susanne, Rose, Adam J., Schwenck, Johannes, Trautwein, Christoph, Karimi, Mohammad M., Heikenwalder, Mathias · 2024 · Cell Metabolism
Cited by 118

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The role and molecular mechanisms of intermittent fasting (IF) in non-alcoholic steatohepatitis (NASH) and its transition to hepatocellular carcinoma (HCC) are unknown. Here, we identified that an IF 5:2 regimen prevents NASH development as well as ameliorates established NASH and fibrosis without affecting total calorie intake. Furthermore, the IF 5:2 regimen blunted NASH-HCC transition when applied therapeutically. The timing, length, and number of fasting cycles as well as the type of NASH diet were critical parameters determining the benefits of fasting. Combined proteome, transcriptome, and metabolome analyses identified that peroxisome-proliferator-activated receptor alpha (PPARα) and glucocorticoid-signaling-induced PCK1 act co-operatively as hepatic executors of the fasting response. In line with this, PPARα targets and PCK1 were reduced in human NASH. Notably, only fasting initiated during the active phase of mice robustly induced glucocorticoid signaling and free-fatty-acid-induced PPARα signaling. However, hepatocyte-specific glucocorticoid receptor deletion only partially abrogated the hepatic fasting response. In contrast, the combined knockdown of Ppara and Pck1 in vivo abolished the beneficial outcomes of fasting against inflammation and fibrosis. Moreover, overexpression of Pck1 alone or together with Ppara in vivo lowered hepatic triglycerides and steatosis. Our data support the notion that the IF 5:2 regimen is a promising intervention against NASH and subsequent liver cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2024.04.015

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 118

Metadata

Authors
Gallage, S., Ali, A., Barragan Avila, J. E., Seymen, N., Ramadori, P., Joerke, V., Zizmare, L., Aicher, D., Gopalsamy, I. K., Fong, W., Kosla, J., Focaccia, E., Li, X., Yousuf, S., Sijmonsma, T., Rahbari, M., Kommoss, K. S., Billeter, A., Prokosch, S., Rothermel, U., Mueller, F., Hetzer, J., Heide, D., Schinkel, B., Machauer, T., Pichler, B., Malek, N. P., Longerich, T., Roth, S., Rose, A. J., Schwenck, J., Trautwein, C., Karimi, M. M., & Heikenwalder, M.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2024-06
Volume
36
Issue
6
Pages
1371-1393.e7
ISSN
1550-4131 (ISSN-L)
OpenAlex
W4396691510
Cited by
118
References
24
FWCI
27.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1. https://app.cochat.ai/papers/10.1016/j.cmet.2024.04.015
The paper
Gallage, S., Ali, A., Barragan Avila, J. E., Seymen, N., Ramadori, P., Joerke, V., Zizmare, L., Aicher, D., Gopalsamy, I. K., Fong, W., Kosla, J., Focaccia, E., Li, X., Yousuf, S., Sijmonsma, T., Rahbari, M., Kommoss, K. S., Billeter, A., Prokosch, S., . . . Heikenwalder, M. (2024). A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1. Cell Metabolism. https://doi.org/10.1016/j.cmet.2024.04.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.